Pegpleranib Sodium(Pegpleranib Sodium) - 药物靶点：PDGF_专利_临床

概要

基本信息

药物类型

适配体

别名

Fovista、Pegpleranib、DD50D2QKH1 (UNII code)

+ [7]

靶点

PDGF

作用方式

抑制剂

作用机制

PDGF抑制剂(血小板源性生长因子抑制剂)

治疗领域

遗传病与畸形眼部疾病心血管疾病+ [3]

在研适应症-

非在研适应症

脉络膜新生血管黄斑变性纤维化+ [4]

原研机构

Archemix Corp.

在研机构-

非在研机构

Ophthotech Corp. (New Jersey)

IVERIC bio, Inc.

National Eye Institute

权益机构

Oldtech, Inc.

Novartis AG

IVERIC bio, Inc.

最高研发阶段终止临床3期

首次获批日期-

最高研发阶段(中国)-

特殊审评-

登录后查看时间轴

结构/序列

Sequence Code 239098577

来源: *****

关联

12

项与 Pegpleranib Sodium 相关的临床试验

NCT02859441

/ Completed临床1/2期IIT

A Phase I/II Trial for Intravitreous Treatment of Severe Ocular Von Hippel-Lindau Disease Using a Combination of the PDGF Antagonist E10030 and the VEGF Antagonist Ranibizumab

Background: People with Von-Hippel-Lindau (VHL) disease may experience significant vision loss as a result of retinal capillary hemangiomas (RCH), the most common and often earliest manifestation of VHL.
Objective: To investigate the safety and possible efficacy of combination investigational treatment with serial intravitreal injections of E10030, a PDGF-B antagonist, and ranibizumab, a VEGF-A antagonist, in participants with severe ocular VHL disease.
Design: Three participants with severe ocular VHL disease will receive the combination investigational treatment in one eye and will be followed for 104 weeks.
Primary Outcome: The safety of the combination investigational treatment, assessed by tabulation of adverse events reported through Week 52.

开始日期2017-01-23

申办/合作机构

National Eye Institute

EUCTR2015-000518-23-CZ

/ Terminated临床2期

A phase 2b randomized, double-masked, controlled trial to establish the safety and efficacy of intravitreous administration of Fovista® (Anti-PDGFBB pegylated aptamer) administered in combination with Avastin® compared to Avastin® monotherapy in subjects with subfoveal neovascular age-related macular degeneration.

开始日期2016-08-31

申办/合作机构

Ophthotech Corp. (New Jersey)

NCT02387957

/ Terminated临床2期

A 24 Month Phase 2a Open Label, Randomized Study of Avastin®, Lucentis®, or Eylea® (Anti-VEGF Therapy) Administered in Combination With Fovista® (Anti-PDGF BB Pegylated Aptamer)

To evaluate the safety of intravitreal (IVT) Fovista® administered in combination with anti-VEGF therapy.

开始日期2016-04-26

申办/合作机构

Ophthotech Corp. (New Jersey)

100 项与 Pegpleranib Sodium 相关的临床结果

登录后查看更多信息

100 项与 Pegpleranib Sodium 相关的转化医学

登录后查看更多信息

100 项与 Pegpleranib Sodium 相关的专利（医药）

登录后查看更多信息

7

项与 Pegpleranib Sodium 相关的文献（医药）

2017-07-03·Expert opinion on emerging drugs2区 · 医学

Emerging vascular endothelial growth factor antagonists to treat neovascular age-related macular degeneration

2区 · 医学

Review

作者: Thomas A. Ciulla ; Rehan M Hussain

INTRODUCTION:

Evolving anti-vascular endothelial growth factor (VEGF) treatments for neovascular age-related macular degeneration (nAMD) include long acting agents, combination strategies involving new pathways, topical agents, sustained-release, and genetic therapy strategies. Areas covered: Brolucizumab and abicipar pegol have smaller molecular size, facilitating higher concentrations and potentially longer duration than current anti-VEGF agents. Agents being combined with anti-VEGFs include OPT-302 (to inhibit VEGF-C and VEGF-D); pegpleranib and rinucumab (to inhibit platelet derived growth factor, PDGF - but both failed to show consistently improved visual outcomes compared to anti-VEGF monotherapy); and RG7716, ARP-1536 and nesvacumab (to activate the Tie-2 tyrosine kinase receptor, which reduces permeability). X-82 is an oral anti-VEGF and anti-PDGF being tested in phase 2 studies. Topical anti-VEGF ± anti-PDGF drugs under study include pazopanib, PAN-90806, squalamine lactate, regorafinib, and LHA510. Sustained-release anti-VEGF delivery treatments, such as the ranibizumab Port Delivery System, GB-102, NT-503, hydrogel depot, Durasert, and ENV1305 aim to reduce the burden of frequent injections. Gene therapies with new viral vectors hold the potential to induce sustained expression of anti-angiogenic proteins via the retina's cellular apparatus, and include AVA-101/201, ADVM-202/302, AAV2-sFLT01, RGX314, and Retinostat. Expert opinion: There are many emerging anti-VEGF treatments that aim to improve visual outcomes and reduce the treatment burden of nAMD.

2017-02-01·Ophthalmology1区 · 医学

Dual Antagonism of PDGF and VEGF in Neovascular Age-Related Macular Degeneration

1区 · 医学

Article

作者: Eandi, Chiara M ; Ciardella, Antonio P ; Jaffe, Glenn J ; Ciulla, Thomas A ; Westby, Keith ; Masonson, Harvey ; Patel, Samir C ; Monés, Jordi ; Pearlman, Joel A ; Dugel, Pravin U ; Quaranta-El Maftouhi, Maddalena ; Devin, Francois ; Ricci, Federico

PURPOSE:

To assess the safety and efficacy of E10030 (Fovista; Ophthotech, New York, NY), a platelet-derived growth factor (PDGF) antagonist, administered in combination with the anti-vascular endothelial growth factor (VEGF) agent ranibizumab (Lucentis; Roche, Basel, Switzerland) compared with ranibizumab monotherapy in patients with neovascular age-related macular degeneration (nAMD).

DESIGN:

Phase IIb global, multicenter, randomized, prospective, double-masked, controlled superiority trial.

PARTICIPANTS:

Four hundred forty-nine patients with treatment-naïve nAMD.

METHODS:

Participants were randomized in a 1:1:1 ratio to 1 of the following 3 intravitreal treatment groups: E10030 0.3 mg in combination with ranibizumab 0.5 mg, E10030 1.5 mg in combination with ranibizumab 0.5 mg, and sham in combination with ranibizumab 0.5 mg (anti-VEGF monotherapy). Drugs were administered monthly in each of the groups for a total duration of 24 weeks.

MAIN OUTCOME MEASURES:

The prespecified primary end point was the mean change in visual acuity (VA; Early Treatment Diabetic Retinopathy [ETDRS] letters) from baseline to 24 weeks.

RESULTS:

No significant safety issues were observed in any treatment group. The E10030 (1.5 mg) combination therapy regimen met the prespecified primary end point of superiority in mean VA gain compared with anti-VEGF monotherapy (10.6 compared with 6.5 ETDRS letters at week 24; P = 0.019). A dose-response relationship was evident at each measured time point commencing at 4 weeks. Visual acuity outcomes favored the E10030 1.5 mg combination therapy group regardless of baseline VA, lesion size, or central subfield thickness on optical coherence tomography. All clinically relevant treatment end points of visual benefit (≥15 ETDRS letter gain, final VA ≥20/40 or ≥20/25) and visual loss (≥1 ETDRS line loss, ≥2 ETDRS line loss, final VA ≤20/125 or ≤20/200) favored the E10030 1.5 mg combination group.

CONCLUSIONS:

In this phase IIb clinical trial, a 62% relative benefit from baseline was noted in the E10030 1.5 mg combination therapy group compared with the anti-VEGF monotherapy group. A favorable safety and efficacy profile of E10030 combination therapy for nAMD was evident across multiple clinically relevant end points. This highly powered study provides strong rationale for a confirmatory phase III clinical trial.

2017-02-01·Ophthalmic surgery, lasers & imaging retina4区 · 医学

An Overview of the Fovista and Rinucumab Trials and the Fate of Anti-PDGF Medications

4区 · 医学

Review

作者: Dunn, Evan N. ; Sheth, Veeral S. ; Hariprasad, Seenu M.

SLACK Incorporated’s journal copyright agreements enable authors funded by the National Institutes of Health (NIH) to deposit their accepted manuscripts to PubMed Central for posting 12 months following publication by SLACK Incorporated. The agreement also allows posting of accepted manuscripts on authors’ institutional repositories, with the exception of open access repositories, 12 months following publication by SLACK Incorporated. Authors should include a link to the final published article on the journal website. SLACK Incorporated will retain copyright for these articles, which prohibits republication elsewhere, and SLACK Incorporated will retain the right to charge a fee for the final published versions of these articles in whatever format they appear.

6

项与 Pegpleranib Sodium 相关的新闻（医药）

2026-02-07

·医药企业项目管理大会

带你学习药物靶点 | 新药发现

会议推荐 2026第三届中国医药企业项目管理大会 2026第二届中国AI项目管理大会 2026第十五届中国PMO大会 2026第五届中国项目经理大会本文目录 1、日拱一卒药物靶点篇 2、ADC详解系列第一期--靶点篇 3、【药物宝典】靶点知多少! 一、日拱一卒药物靶点篇（原创小胡子才是本体大脑触点）新药发现的过程包含了药物靶点的选择和确认、先导化合物的发现途径、临床前研究、临床研究申请、临床研究、批准上市等基础阶段，今天先来了解一下什么是药物靶点。药物靶点是现代药物研发的核心，它决定了药物的作用机制和疗效。一个理想的药物靶点不仅能有效治疗疾病，还能最大限度地减少副作用，提高患者的生活质量。什么是药物靶点? What is Drug Target? 药物靶点是指体内具有药效功能并能被药物作用的生物大分子，包括受体、酶、离子通道、核酸等生物大分子。那些编码靶点蛋白的基因也被称为靶点基因。 Drug targets are biomolecules in the body that have pharmacodynamic functions and can be acted upon by drugs, including receptors, enzymes, ion channels, nucleic acids and other biomolecules. Those genes that encode target proteins are also known as target genes. 事先确定靶向特定疾病有关的靶点分子是现代新药开发的基础。 Prior identification of target molecules associated with specific diseases is the basis of modern new drug development. 药物靶点研究的必要性 The Necessity of Drug Target Study 针对靶点的研究明确了疾病症结所在，也就确定了新药的研发方向，缩小了筛选范围，做到新药研发有的放矢。 The research on the target site clarifies the crux of the disease, and also determines the direction of new drug research and development, narrowing down the scope of screening, so as to achieve new drug research and development in a targeted manner. 靶点的研究有助于了解药物作用机制，进而对已有药物进行改造，研发出毒性更小、选择性更强、治疗效果更好的新药。 The study of targets helps to understand the mechanism of drug action, which in turn leads to the modification of existing drugs and the development of new drugs that are less toxic, more selective and more therapeutically effective. 新药发现与药物靶点 New Drug Discovery and its Target 基于靶点的药物发现模式逐渐取代了传统的基于药物化学结构的发现模式,成为现代创新药物研发的主流模式。 The target-based drug discovery model has gradually replaced the traditional discovery model based on the chemical structure of drugs, and has become the mainstream model of modern innovative drug discovery. 表1 药靶实例 Examples of drug targets 表2 近年来的部分靶点 Selected targets in recent years 二、ADC详解系列第一期--靶点篇（原创清静无为爱医时空）前言 ADC（Antibody–Drug Conjugates），全称“抗体偶联药物”，是一类抗体、连接头和细胞毒性药物组成的靶向药物，以单克隆抗体为载体将细胞毒药物以靶向方式高效地运输至目标肿瘤细胞中，兼具传统化疗的强大杀伤效应及抗体药物的肿瘤靶向性。理想的ADC药物在血液循环中保持稳定，精准到达治疗目标，并最终在目标附近（如癌细胞）释放细胞毒性有效载荷。为了使ADC药物实现理想的疗效和安全性，在构建ADC时需要综合考虑五大核心要素：靶点、抗体、连接子、毒素和偶联方式。图1. ADC药物的结构和特性[1] ADC作用机制始于与靶细胞的结合，肿瘤细胞上表达的靶抗原是ADC药物识别肿瘤细胞的指导方向，而且ADC药物与抗原结合后，还要能够被细胞内吞，在肿瘤细胞内转运和降解。因此，选择合适的靶点是ADC的首要考虑因素之一。靶点特性理想的靶点应具备以下特点：（1）组织特异性强：为了降低脱靶毒性，靶向抗原应仅表达或主要表达在肿瘤细胞中，在正常组织中低表达或不表达。例如，与正常细胞相比，某些肿瘤中HER2的表达大约高出正常细胞100倍；（2）抗原稳定性高：为避免肿瘤靶向性降低和安全性问题，靶向抗原应是表面（或细胞外）抗原，而不是细胞内抗原，且靶抗原应当是非分泌的，以避免被循环系统识别；（3）抗原高效内化：理想的靶抗原在与相应抗体结合后能够内化，使ADC药物进入癌细胞，通过适当的细胞内运输途径和释放细胞毒性有效载荷。目前获批ADC药物针对的靶抗原通常是癌细胞过表达的特异性蛋白，包括实体瘤中靶点HER2、Trop2、Nectin4和EGFR，以及血液恶性肿瘤靶点CD19、CD22、CD33、CD30、BCMA和CD79b。在肿瘤学和免疫学基础研究的推动下，ADC靶抗原的选择已逐渐从传统的肿瘤细胞抗原扩展到肿瘤微环境中的靶标（如在基质和脉管系统）。图2. ADC药物靶点选择（肿瘤细胞和肿瘤微环境）[1] 已批准上市的ADC靶点自第一个ADC药物Mylotarg®（gemtuzumab ozogamicin）于2000年获得FDA批准以来，截至2024年，目前全球共有14款ADC药物获批用于血液系统恶性肿瘤和实体瘤。这14款ADC药物对应12个靶点，分别为HER2、CD22、BCMA、CD33、CD30、CD79b、Nectin-4、EGFR、CD19、TissueFactor（TF）、FRα和Trop2。表1. 上市ADC药物靶点[1，2] ADC靶点研发情况据统计，全球有800多款ADC药物处于不同研发阶段，ADC药物的热门靶点有HER2、Trop2、EGFR、c-Met、B7-H3、HER3、Nectin-4、CLDN18.2、PDL1等多个成熟的靶点。图3. 全球在研ADC靶点分布（排名前20位）[2] 肺癌领域ADC药物常见靶点 ADC药物在肺癌领域中的探索主要针对HER2，HER3，Trop2，MET，CEACAM5，B7-H3等靶点（图4），并展现出了极大的应用潜力。图4. 肺癌ADC药物靶点概述[3] 1. HER2靶点 HER2是一种受体酪氨酸激酶（RTK），被认为是非小细胞肺癌（NSCLC）的治疗靶点。由于HER2比其他HER家族成员更不容易发生内化和降解，这些成员表现出更高的受体转换，因此它可以在细胞膜上保持较长时间的活化，代表了ADC研发理论的理想靶点。 2. HER3靶点 HER3是RTK HER家族的另一个成员，通常在NSCLC中表达（高达83%）。HER3异源二聚化是EGFR酪氨酸激酶抑制剂（TKI）耐药的一种机制，通过增强HER3依赖性致癌信号激活发挥作用。 3. Trop2靶点 Trop2是上皮细胞粘附分子（EpCAM）家族的跨膜糖蛋白，在多数肿瘤中表达，但偶尔在正常组织中表达。 4. CEACAM5靶点癌胚抗原相关细胞黏附分子（CEACAMs）是一类细胞表面糖蛋白家族。CEACAM5在几种肿瘤类型中有选择性地表达，包括肺癌。 5. MET靶点 MET是肝细胞生长因子的酪氨酸激酶受体，在NSCLC中，MET过表达约有30%-50%，而MET扩增（1.5%）或MET外显子14跳跃突变（3%）是主要致癌驱动因素。 6. B7-H3靶点 B7-H3（又称CD276）是B7家族蛋白重要的免疫检查点分子，其配体尚不明确，在癌细胞中高度表达。在肺癌领域，除上述靶点外，EGFR、AXL、PVRL4等其他靶点，也都在临床开发中。表2. 肺癌临床研发中ADC药物的靶点汇总[3] 结语综上所述，ADC赛道的竞争日趋白热化，靶点布局同质化问题严重，大多靶点都处于临床疗效验证阶段。如何从技术、适应症等不同维度优化靶点选择，差异化靶点优势，是今后探索的方向。三、【药物宝典】靶点知多少! （原创小派计算机辅助药物设计 CADD） 01 浅谈靶点 What is the target 常见靶向药靶点图药物靶点的发现方法有以下几种： 1、从有效单体化合物着手发现药物靶点 2、以正常组织与病理组织基因表达差异发现靶点 3、通过定量分析和比较研究在正常和疾病状态下蛋白质表达谱的改变发现靶点 4、以蛋白质相互作用为基础发现药物靶标 5、应用RNA干扰技术特异的抑制细胞中不同基因的表达，通过细胞的表型变化发现靶标 02 靶点汇总热门靶点汇总分析 1.Bcr-Abl抑制剂 Bcr-Abl抑制剂主要用于治疗慢性粒细胞白血病( CML) ,目前FDA已经批准伊马替尼、尼罗替尼、达沙替尼、ponatinib 等多个药物,其中第三代Bcr-Abl抑制剂ponatinib可克服T315I耐药突变。 2.VEGF/VEGFRs抑制剂 VEGF/VEGFRs是经典的血管生成信号通路,可用于治疗多种实体瘤和湿性年龄相关性黄斑变性( AMD ) , FDA已经批准的针对VEGF/NVEGFRs 单抗或融合蛋白有贝伐珠单抗、雷珠单抗、阿柏西普、ramucirumab ,我国自主研发的康柏西普已于2013年上市。 3.PDGF/PDGFRs抑制剂 PDGFRs与VEGFRs的相似度较高很多小分子药物是VEGFRs/PDGFRs同时抑制的,比如索拉非尼、舒尼替尼、帕唑帕尼。2014年1月Bayer支付2550万美元携手Regeneron ,共同开发anti- PDGFRβ单抗,联合阿柏西普用于治疗湿性AMD ; 2014年5月Novartis以10.3亿美元从Ophthotech Corporation买下II期anti-PDGF药物Fovista ,用于治疗湿性AMD。 4.HGF/c-Met抑制剂 c-Met别名HGFR ,与其他生长因子受体一样,也是抗癌药研发的热门靶点，已经.上市的c-Met抑制剂有克唑替尼、卡博替尼,但这两个分子抑制c-Met的同时还抑制了其他靶点。onartuzumab、 tivantinib 治疗非小细胞肺癌的II期临床失败对选择性c-Met抑制剂的研发是个重大打击,可能需要寻找更好的患者筛选方法或适应症。 5.ALK抑制剂 ALK通过基因融合而激活致癌, 70-80%间变性大细胞淋巴瘤存在NPM-ALK融合,6.7%的非小细胞肺癌存在EML4-ALK融合。FDA 批准的第一个ALK抑制剂是克唑替尼,用于治疗ALK阳性非小细胞肺癌,但克唑替尼对c-Met、RON也有抑制作用。第二代ALK抑制剂不再抑制c-Met ,能够克服克唑替尼耐药性, ceritinib、alectinib都获得了FDA突破性药物资格。国内自主研发的ALK抑制剂有江苏豪森的氟卓替尼、北京赛林泰的CT-707。 6.CDK抑制剂 CDK全称细胞周期蛋白依赖性激酶,有CDK1-11等多个亚型,能够与细胞周期蛋白结合,调节细胞周期。Palbociclib、 LEE011、 LY2835219 等三个CDK4/6抑制剂都已进入后期开发,用于治疗乳腺癌。 7.PARP抑制剂 PARP能够识别DNA单链断点启动修复, 最初开发PARP抑制剂用于增强化疗药物的疗效,后来主要针对DNA修复缺陷型癌症。 8.Bcl-2抑制剂 Bcl-2蛋白家族是一类重要的凋亡调节因子,包括抗凋亡蛋白(如Bcl-2、 Bcl-xL、Mcl-1 )和促凋亡蛋白(如BID、BIM、 BAD、 BAK、 BAX、 NOXA)。Bcl-2 和Bcl-xL在许多肿瘤中过度表达,诱导癌细胞对癌症的治疗产生耐性。药物研发如何选择正确的靶点 03 靶点选择肿瘤靶向药物：靶点的选择应满足哪些条件靶向肿瘤基质细胞 end 本公众号声明： 1、如您转载本公众号原创内容必须注明出处。 2、本公众号转载的内容是出于传递更多信息之目的，若有来源标注错误或侵犯了您的合法权益，请作者或发布单位与我们联系，我们将及时进行修改或删除处理。 3、本公众号文中部分图片来源于网络，版权归原作者所有，如果侵犯到您的权益，请联系我们删除。 4、本公众号发布的所有内容，并不意味着本公众号赞同其观点或证实其描述。其原创性以及文中陈述文字和内容未经本公众号证实，对本文全部或者部分内容的真实性、完整性、及时性我们不作任何保证或承诺，请浏览者仅作参考，并请自行核实。

抗体药物偶联物

2023-05-01

·FierceBiotech

Astellas keeps the big buyouts rolling, inking $5.9B Iveric takeover ahead of FDA eye disease ruling

Astellas framed the deal to buy Iveric Bio as a way to further its focus on blindness and regeneration. The multibillion-dollar biotech buyouts keep on coming. Astellas Pharma is the latest drugmaker to get in on the act, agreeing to pay $5.9 billion to buy Iveric Bio and establish itself as a player in an emerging eye disease niche. Iveric is less than three months away from learning whether the FDA will approve avacincaptad pegol, a complement C5 protein inhibitor that reduced the rate of geographic atrophy (GA) progression in a phase 3 clinical trial. Patients with GA, a cause of irreversible loss of vision in patients with age-related macular degeneration (AMD), lacked treatments until recently, but the market is heating up fast. Apellis Pharmaceuticals won the first FDA approval for a GA drug, Syfovre, in February, and companies including AstraZeneca, Johnson & Johnson, Novartis and Roche are in pursuit. Iveric, a biotech formerly known as Ophthotech, is poised to be the first commercial rival to Apellis, though. That fact has caught Astellas’ attention. Astellas has agreed to pay $40 per share in cash to buy Iveric. The fee represents a 22% premium over Iveric’s closing price at the end of last week. That may seem light in the wake of the triple-digit premiums that GSK and Sanofi have paid recently for Bellus Health and Provention Bio, respectively, but it follows a steady rise in Iveric’s share price. The premium over Iveric’s March 31 share price is 64%. The willingness of Astellas to pay $5.9 billion for Iveric reflects the Japanese drugmaker’s desire to hit its 2025 sales target and need to add new growth drivers to offset the anticipated loss of revenue when the prostate cancer drug Xtandi loses patent protection in 2027. Astellas also framed the deal as a way to further its focus on blindness and regeneration. Cell and gene therapies are part of the strategy, but that side of the pipeline has stuttered, with enrollment in a phase 1 trial of GA candidate ASP7317 stopping for two years and a glaucoma prospect acquired in the Quethera buyout yet to reach the clinic. Buying Iveric will give Astellas a GA drug that could be approved by the time the deal closes in the third quarter and accelerate an expansion into ophthalmology by providing control of the commercial team and other infrastructure that the biotech has built up to support the launch. Earlier this year, Iveric said it was building a 120-person sales team that would include 50 to 70 field-based reps. The deal completes an impressive recovery for Iveric, which was on the ropes in 2017. Back then, a run of three clinical trial failures for Fovista sunk the biotech’s stock and wiped out the optimism generated when Novartis paid $200 million for ex-U.S. rights to the AMD asset. Yet, Iveric recovered, changing its name from Ophthotech and embarking on a GA strategy that culminates today in the Astellas buyout.

并购临床1期临床3期上市批准

2021-04-05

·BioSpace

Iveric Bio’s Co-Founder Leaves to Return to Venture Capitalist Role

IVERIC bio’s co-founder and Executive Chairman David R. Guyer is stepping down from his role to return to his first love – investing. He’ll make a return to his former role at SV Health Investors as a Venture Partner. In it from day one, Guyer has guided the company from the boardroom since the retinal disease company’s 2007 inception. Then named Ophthotech, Guyer also led as CEO from 2013-2017. Iveric has been through some highs and lows in Guyer’s time. After a somewhat promising Phase II combination trial, the company’s wet age-related macular degeneration (AMD) drug Fovista flopped badly in Phase III, failing to show any measurable benefit. Guyer had to make the tough call to cut 80% of staff, leaving its headcount at less than 50. From there, the company pivoted toward gene therapies, in-licensing a portfolio of eye disease-related treatments in development. This move led to the renaming of the Ophthotech to Iveric Bio, updating its Nasdaq symbol to the clever “ISEE” on the ticker. Iveric’s lead drug Zimura is a C5 inhibitor currently in development for the treatment of geographic atrophy (GA) secondary to age-related macular degeneration (AMD). Zimura published positive Phase III results last fall and continues in a Phase II study for autosomal recessive Stargardt disease. “I am very excited about Iveric's phase 3 program of Zimura for the treatment of geographic atrophy secondary to age-related macular degeneration and look forward to continuing to serve the company as a senior advisor,” Guyer said. Guyer will remain a senior advisor to Iveric, without the weight of any executive powers. “As a co-founder, former Chief Executive Officer and most recently Executive Chair, David has been an integral part of Iveric Bio’s leadership, a trusted advisor and visionary in retinal medicine, and I sincerely thank him for his hard work and significant contributions to the Company,” stated Glenn P. Sblendorio, chief executive officer and president of Iveric Bio. “Iveric Bio's strong management team has evolved to the point where there is no longer a need for an Executive Chair,” Guyer added. “After more than 14 years on the Board, I feel that this is a good departure point such that I can return to my passion as a venture capitalist."

100 项与 Pegpleranib Sodium 相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
-	-	-	DB06325

研发状态

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
黄斑变性	临床3期	比利时	IVERIC bio, Inc.	2013-08-01
黄斑变性	临床3期	丹麦	IVERIC bio, Inc.	2013-08-01
黄斑变性	临床3期	瑞士	IVERIC bio, Inc.	2013-08-01
黄斑变性	临床3期	土耳其	IVERIC bio, Inc.	2013-08-01
黄斑变性	临床3期	英国	IVERIC bio, Inc.	2013-08-01
湿性年龄相关性黄斑变性	临床3期	美国	Ophthotech Corp. (New Jersey)	2013-08-01
湿性年龄相关性黄斑变性	临床3期	阿根廷	Ophthotech Corp. (New Jersey)	2013-08-01
湿性年龄相关性黄斑变性	临床3期	澳大利亚	Ophthotech Corp. (New Jersey)	2013-08-01
湿性年龄相关性黄斑变性	临床3期	奥地利	Ophthotech Corp. (New Jersey)	2013-08-01
湿性年龄相关性黄斑变性	临床3期	比利时	Ophthotech Corp. (New Jersey)	2013-08-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT02859441 (Pubmed \| Clin Exp Ophthalmol) 人工标引	临床1/2期	希佩尔·林道综合征	3	E10030+ranibizumab	鹹衊築簾餘夢鹹艱鏇膚(觸憲鏇構觸膚簾願鬱艱) = One participant manifested mild episodic ocular hypertension in the study eye 膚鬱鹽廠網餘餘衊願繭 (齋餘簾淵築積憲顧餘餘 ) 更多	不佳	2021-09-21
NCT01940887 (OPH1004, CTgov)	临床3期	湿性年龄相关性黄斑变性	645	aflibercept+E10030+bevacizumab (E10030 + Bevacizumab or Aflibercept)	壓鹹願構餘網壓蓋壓餘(觸餘鹹範獵壓蓋鏇襯鑰) = 夢網廠廠衊範夢簾鏇願壓衊觸餘製顧窪選齋範 (憲遞願構醖醖鬱壓範艱, 0.85) 更多	-	2020-09-30
				aflibercept+E10030 sham injection+bevacizumab (Sham + Bevacizumab or Aflibercept)	壓鹹願構餘網壓蓋壓餘(觸餘鹹範獵壓蓋鏇襯鑰) = 鹽廠構蓋鑰鹽網選選積壓衊觸餘製顧窪選齋範 (憲遞願構醖醖鬱壓範艱, 0.85) 更多
NCT02214628 (CTgov)	临床2期	湿性年龄相关性黄斑变性	101	Fovista (Fovista® (Anti-PDGF BB) Plus Anti-VEGF Simultaneous Regimen)	範廠糧餘築憲鹽膚襯窪 = 範鏇遞淵餘夢積糧淵鏇獵鏇淵艱憲餘衊繭鹹襯 (憲醖蓋製製衊網鑰觸願, 鹹艱顧襯糧獵膚衊糧鏇 ~ 齋選範觸夢窪願齋衊觸) 更多	-	2019-07-10
				Fovista (Fovista® (Anti-PDGF BB) Plus Anti-VEGF Pre-Treatment Regimen)	範廠糧餘築憲鹽膚襯窪 = 鑰製構餘廠構膚蓋餘衊獵鏇淵艱憲餘衊繭鹹襯 (憲醖蓋製製衊網鑰觸願, 繭壓夢餘餘淵鑰繭廠醖 ~ 艱膚獵艱窪觸糧鑰膚願) 更多
NCT02387957 (CTgov)	临床2期	年龄相关性黄斑变性	63	Fovista®+bevacizumab (Fovista® Plus Bevacizumab)	艱構膚獵獵齋簾淵願壓 = 壓願鹽築鬱鏇壓鹹糧夢簾淵襯鑰憲範糧襯鏇壓 (襯夢蓋範餘製蓋積憲憲, 壓壓鹽餘製夢膚憲淵窪 ~ 衊獵獵夢廠選襯壓膚憲) 更多	-	2019-03-05
				ranibizumab+Fovista® (Fovista® Plus Ranibizumab)	艱構膚獵獵齋簾淵願壓 = 觸糧膚願鹹襯構築鹽觸簾淵襯鑰憲範糧襯鏇壓 (襯夢蓋範餘製蓋積憲憲, 簾衊築網網顧繭衊鹹襯 ~ 襯窪蓋齋糧構鹹齋憲鬱) 更多
NCT01940900 (OPH1003, CTgov)	临床3期	湿性年龄相关性黄斑变性	627	ranibizumab+E10030 (E10030 + Ranibizumab)	選鹹鑰窪鏇襯餘餘鏇鹹(獵夢鹽廠醖鹹積鑰廠壓) = 願壓醖鹽壓願顧憲積選齋範壓獵獵膚膚製築範 (襯網艱觸築襯憲糧範簾, 0.88) 更多	-	2018-08-15
				ranibizumab+E10030 sham intravitreal injection (Sham + Ranibizumab)	選鹹鑰窪鏇襯餘餘鏇鹹(獵夢鹽廠醖鹹積鑰廠壓) = 膚簾鬱網願積窪觸夢遞齋範壓獵獵膚膚製築範 (襯網艱觸築襯憲糧範簾, 0.87) 更多
NCT01944839 (OPH1002, CTgov)	临床3期	湿性年龄相关性黄斑变性	619	ranibizumab+E10030 (E10030 + Ranibizumab)	選積淵願窪製餘鹽餘鬱(網網選醖繭製積齋鏇夢) = 築壓鏇襯遞憲鬱夢構夢觸積遞範鑰蓋鑰衊鹽膚 (壓淵淵築醖製繭憲醖鹹, 0.86) 更多	-	2018-08-10
				ranibizumab+E10030 sham intravitreal injection (Sham + Ranibizumab)	選積淵願窪製餘鹽餘鬱(網網選醖繭製積齋鏇夢) = 顧夢構襯鑰襯醖獵鹽膚觸積遞範鑰蓋鑰衊鹽膚 (壓淵淵築醖製繭憲醖鹹, 0.86) 更多
NCT01940887 (OPH1004, PipelineReview) 人工标引	临床3期	湿性年龄相关性黄斑变性	640	Aflibercept+Avastin+Fovista	鑰繭構醖窪構憲觸鏇鑰(鬱餘齋獵壓窪選夢獵齋) = 遞糧憲選醖膚築簾選襯鏇衊鹽範鏇淵築築廠艱 (鏇醖觸齋餘願餘築憲範 )	不佳	2017-08-15
				Aflibercept+Avastin+Placebo	鑰繭構醖窪構憲觸鏇鑰(鬱餘齋獵壓窪選夢獵齋) = 鹹鹽鬱繭鏇膚積網糧範鏇衊鹽範鏇淵築築廠艱 (鏇醖觸齋餘願餘築憲範 )
NCT01940900 (OPH1003, PipelineReview) 人工标引	临床3期	湿性年龄相关性黄斑变性	627	Ranibizumab+Pegpleranib Sodium	鏇鑰鹽鬱衊夢鏇齋鬱繭(餘製鏇餘衊構獵糧範觸) = 窪繭鏇夢構夢鹽選鬱範築願餘膚觸窪觸蓋鹹築 (夢醖齋製襯築積窪壓構 )	不佳	2016-12-12
				Ranibizumab+Placebo	鏇鑰鹽鬱衊夢鏇齋鬱繭(餘製鏇餘衊構獵糧範觸) = 築餘鹽顧淵憲簾簾壓鑰築願餘膚觸窪觸蓋鹹築 (夢醖齋製襯築積窪壓構 )
NCT01944839 (OPH1002, PipelineReview) 人工标引	临床3期	湿性年龄相关性黄斑变性	621	Ranibizumab+Pegpleranib Sodium	齋簾鬱糧鏇顧鏇獵餘積(願觸網簾淵鏇築膚繭餘) = 網憲醖廠衊壓構築積築艱遞構廠選願顧齋艱簾 (製鑰簾齋構鏇選廠糧廠 )	不佳	2016-12-12
				Ranibizumab+Placebo	齋簾鬱糧鏇顧鏇獵餘積(願觸網簾淵鏇築膚繭餘) = 齋鑰鹹鹹蓋壓醖齋鏇鏇艱遞構廠選願顧齋艱簾 (製鑰簾齋構鏇選廠糧廠 )
ARVO2016	临床2期	失明 PDGF \| VEGF	449	Fovista 0.3mg + ranibizumab 0.5mg	簾襯構壓積繭獵鑰鏇構(構夢憲願鹽製齋壓衊鹽) = 鑰膚鹽膚壓餘糧範艱簾鹽顧憲築獵鑰膚網顧衊 (鹽襯蓋鏇鏇憲選蓋憲遞 )	积极	2016-05-01
				Fovista 1.5mg + ranibizumab 0.5mg	簾襯構壓積繭獵鑰鏇構(構夢憲願鹽製齋壓衊鹽) = 壓襯範顧鏇餘鑰積築艱鹽顧憲築獵鑰膚網顧衊 (鹽襯蓋鏇鏇憲選蓋憲遞 )